CytRx Corp. saw its stock rise 7 percent on Thursday following more good news from clinical trials. The West L.A. biopharmaceutical firm announced positive results from a study of a potential treatment for HIV-related skin cancer. Shares rose 25 cents to close at $3.64.

The preliminary findings from the ongoing phase-two trial show that the drug, aldoxorubicin, decreased skin lesions and the number of cancer cells, the company said. The treatment also prevented tumor progression in the patients with lung tumors.

CytRx also reported positive results earlier this week from the ongoing phase-two trial of the same drug in the treatment of a form of brain cancer. The stock rose 16 percent on Tuesday on that news.